Propranolol Dosing for Subacute Thyroiditis

Clinical Context and Indication

The American Society of Clinical Oncology recommends beta-blocker therapy, such as propranolol, for symptomatic relief of autonomic hyperactivity in subacute thyroiditis, with a typical dosing range of 40-160 mg daily in divided doses 1
Subacute thyroiditis typically presents with a self-limited thyrotoxic phase that resolves within weeks, most commonly transitioning to hypothyroidism, and beta-blockers do not affect the underlying thyroid pathology or disease course 1

The American Society of Clinical Oncology guideline states that beta-blocker therapy, such as atenolol or propranolol, can be used for symptomatic relief across all severity grades (G1-G3) without a specific dose requirement 1
For patients with mild symptoms (G1), beta-blocker therapy can be used for symptomatic relief with close monitoring every 2-3 weeks to detect transition to hypothyroidism 1
For patients with moderate symptoms (G2), consideration of holding causative agents and adding hydration and supportive care alongside beta-blockade is recommended 1
For patients with severe symptoms (G3-4), hospitalization, holding causative agents, and consideration of endocrine consultation for additional therapies beyond beta-blockade are recommended 1

Absolute contraindications for beta-blocker therapy include second or third-degree heart block, decompensated heart failure, asthma or obstructive airway disease, cardiogenic shock, and hypotension 1, 2, 3
Baseline evaluation should include measurement of heart rate and blood pressure, cardiovascular examination with auscultation, and screening for history of bronchospasm, diabetes, and concurrent medications affecting cardiac conduction 2, 3

Thyroid function (TSH, FT4) should be checked every 2-3 weeks after diagnosis to catch the transition to hypothyroidism, which is the most common outcome 1
Beta-blocker therapy is temporary and symptom-driven, typically needed only during the thyrotoxic phase (usually weeks), and should be gradually tapered when discontinuing after chronic use to prevent rebound hypertension or tachycardia 1, 2

Common adverse effects of beta-blocker therapy include fatigue, bradycardia, hypotension, dizziness, and cold extremities 2, 3
Special populations, such as diabetic patients, may require counseling on the potential for beta-blockers to mask hypoglycemia symptoms 2, 3
Drug interactions, such as the avoidance of routine combination with non-dihydropyridine calcium channel blockers, should be considered 2
Administration of beta-blockers should be done with food to reduce the risk of hypoglycemia, and doses should be held during times of diminished oral intake or vomiting 2, 4